menu
    • menu

    Company profile for SinoMab BioScience

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    SinoMab BioScience Limited (“SinoMab” or the “Company”, stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company’s flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis and is currently in Phase III clinical trial for rheumatoid arthritis ...
    SinoMab BioScience Limited (“SinoMab” or the “Company”, stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company’s flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Thirteenth Five-Year Plan Period.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SinoMab BioScienceChina Flag
    Country
    Country
    China
    Address
    Address
    Units 303 and 305 to 307, No.15 Science Park West Avenue, Hong Kong Science Pa...
    Telephone
    Telephone
    +852 3426 9833
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.sinomab.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/sinomab-bioscience-ltd-
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    SinoMab Dosed First Healthy Subject in PI Trial of SM17 in the U.S.
    SinoMab Dosed First Healthy Subject in PI Trial of SM17 in the U.S.

    15 Jun 2022

    // ASIAONE

    https://www.asiaone.com/business/sinomab-dosed-first-healthy-subject-phase-i-clinical-trial-sm17-us

    ASIAONE
    15 Jun 2022
    Share Share
    Everest inks $561M biobucks deal for renal disease treatment
    Everest inks $561M biobucks deal for renal disease treatment

    18 Sep 2021

    // Kyle LaHucik FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/everest-inks-second-deal-week-will-pay-up-to-561m-for-sinovent-sinomab-for-renal-diseases

    Kyle LaHucik FIERCEBIOTECH
    18 Sep 2021
    Share Share
    Everest Medicines, Sinovent & SinoMab sign deal for BTKi in Renal Diseases
    Everest Medicines, Sinovent & SinoMab sign deal for BTKi in Renal Diseases

    16 Sep 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/everest-medicines-sinovent-and-sinomab-announce-licensing-agreement-for-global-development-manufacturing-and-commercialization-of-novel-btk-inhibitor-in-renal-diseases-301378911.html

    PRNEWSWIRE
    16 Sep 2021
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search